Adimmune Corp (4142) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.073x

Based on the latest financial reports, Adimmune Corp (4142) has a cash flow conversion efficiency ratio of -0.073x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-355.08 Million ≈ $-11.19 Million USD) by net assets (NT$4.85 Billion ≈ $152.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Adimmune Corp - Cash Flow Conversion Efficiency Trend (2007–2024)

This chart illustrates how Adimmune Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 4142 total liabilities for a breakdown of total debt and financial obligations.

Adimmune Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Adimmune Corp ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Lewis Group Limited JSE:LEW	-0.019x
Ernst Russ AG XETRA:HXCK	0.066x
Sight Sciences Inc NASDAQ:SGHT	-0.136x
VIETNAM HOLDING LTD F:2YL	N/A
Otovo AS OL:OTOVO	-0.387x
American Resources Corp Class A NASDAQ:AREC	0.006x
National Aerospace Fasteners Corp TW:3004	0.016x
Steamships Trading Company Ltd AU:SST	0.095x

Annual Cash Flow Conversion Efficiency for Adimmune Corp (2007–2024)

The table below shows the annual cash flow conversion efficiency of Adimmune Corp from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see 4142 company net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	NT$5.56 Billion ≈ $175.22 Million	NT$668.48 Million ≈ $21.06 Million	0.120x	+177.82%
2023-12-31	NT$5.78 Billion ≈ $182.03 Million	NT$-892.35 Million ≈ $-28.11 Million	-0.154x	-246.22%
2022-12-31	NT$6.54 Billion ≈ $206.20 Million	NT$-291.96 Million ≈ $-9.20 Million	-0.045x	+40.28%
2021-12-31	NT$6.43 Billion ≈ $202.66 Million	NT$-480.52 Million ≈ $-15.14 Million	-0.075x	-121.33%
2020-12-31	NT$6.63 Billion ≈ $208.84 Million	NT$2.32 Billion ≈ $73.15 Million	0.350x	+630.21%
2019-12-31	NT$3.83 Billion ≈ $120.53 Million	NT$-252.72 Million ≈ $-7.96 Million	-0.066x	+79.62%
2018-12-31	NT$1.86 Billion ≈ $58.48 Million	NT$-601.74 Million ≈ $-18.96 Million	-0.324x	-11178.96%
2017-12-31	NT$2.35 Billion ≈ $74.02 Million	NT$6.87 Million ≈ $216.57K	0.003x	+101.17%
2016-12-31	NT$3.09 Billion ≈ $97.51 Million	NT$-773.53 Million ≈ $-24.37 Million	-0.250x	-146.38%
2015-12-31	NT$3.68 Billion ≈ $116.09 Million	NT$-373.82 Million ≈ $-11.78 Million	-0.101x	-8.59%
2014-12-31	NT$4.47 Billion ≈ $140.75 Million	NT$-417.35 Million ≈ $-13.15 Million	-0.093x	+46.82%
2013-12-31	NT$3.24 Billion ≈ $101.99 Million	NT$-568.64 Million ≈ $-17.92 Million	-0.176x	-60.56%
2012-12-31	NT$3.74 Billion ≈ $117.92 Million	NT$-409.48 Million ≈ $-12.90 Million	-0.109x	-34.00%
2011-12-31	NT$3.60 Billion ≈ $113.37 Million	NT$-293.77 Million ≈ $-9.26 Million	-0.082x	-164.23%
2010-12-31	NT$4.06 Billion ≈ $127.99 Million	NT$516.39 Million ≈ $16.27 Million	0.127x	-20.26%
2009-12-31	NT$3.77 Billion ≈ $118.67 Million	NT$600.42 Million ≈ $18.92 Million	0.159x	+472.28%
2008-12-31	NT$3.17 Billion ≈ $99.84 Million	NT$-135.69 Million ≈ $-4.28 Million	-0.043x	-363.61%
2007-12-31	NT$1.92 Billion ≈ $60.63 Million	NT$31.26 Million ≈ $984.86K	0.016x	--

About Adimmune Corp

TW:4142 Taiwan Biotechnology

Market Cap

$235.05 Million

NT$7.46 Billion TWD

Market Cap Rank

#15934 Global

#729 in Taiwan

Share Price

NT$17.70

Change (1 day)

-1.39%

52-Week Range

NT$16.00 - NT$21.55

All Time High

NT$77.19